Anticorps Monoclonal anti-CD85j / LILRB1

CD85j / LILRB1 Monoclonal Antibody for FC

Hôte / Isotype

Mouse / IgG2b, kappa

Réactivité testée

Humain

Applications

FC

Conjugaison

CoraLite® Plus 594 Fluorescent Dye

CloneNo.

GHI/75

N° de cat : CL594-65238

Synonymes

LILRB1, ILT 2, GHI/75, FLJ37515, CD85j



Applications testées

Résultats positifs en cytométrieCMSP humaines,

Dilution recommandée

ApplicationDilution
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood.
Sample-dependent, check data in validation data gallery

Informations sur le produit

CL594-65238 cible CD85j / LILRB1 dans les applications de FC et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Mouse / IgG2b, kappa
Clonalité Monoclonal
Type Anticorps
Immunogène Human Hairy Cell Leukemia Spleen Cells
Nom complet leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Masse moléculaire calculée 71 kDa
Numéro d’acquisition GenBankBC015731
Symbole du gène LILRB1
Identification du gène (NCBI) 10859
Conjugaison CoraLite® Plus 594 Fluorescent Dye
Excitation/Emission maxima wavelengths594 nm / 615 nm
Forme Liquide
Méthode de purification N/A
Tampon de stockage PBS with 0.09% sodium azide and 0.5% BSA
Conditions de stockageStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

Informations générales

LILRB1, also named as CD85j or ILT2, includes four C2 Ig domains binding HLA class I molecules in the extracellular region and a cytoplasmic domain containing four immunoreceptor tyrosine-based inhibition motifs (ITIM). LILRB1 is a surface glycoprotein detected on the surface of B cells, monocytes, dendritic cells, T cells and NK cells.

Protocole

Product Specific Protocols
FC protocol for CL Plus 594 CD85j / LILRB1 antibody CL594-65238Download protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}